Can Stimulating Select Cannabinoid Receptors Stave Off Depression?

In some, stress-induced depression and anxiety can become debilitating.  Unfortunately, these disorders are some of the most prevalent worldwide.  In an effort to attain a greater understanding of both the workings and potential treatments for these disorders, researchers from the Université Laval recently published a paper that looked at why some individuals demonstrate surprising resilience over prolonged periods.  Their findings go beyond interesting and could potentially open new doors for targeted mental health treatments involving cannabis.

CB1 Receptors and Stress Responses

It all boils down to the presence of cannabinoid receptor 1 (CB1) on astrocytes within specific brain regions.  As we know, the endocannabinoid system plays a crucial role in regulating stress responses, mood, and cognitive function.  CB1 receptors, which are predominantly found in neurons, are also present in astrocytes—non-neuronal support cells that regulate neurovascular function and maintain the integrity of the blood-brain barrier (BBB).  The study found that mice with higher levels of CB1 receptors in astrocytes of the nucleus accumbens (NAc) shell exhibited significant resilience to chronic social stress.

What allowed for this insight was an approach that saw the researchers selectively increase CB1 receptor expression in astrocytes.  Upon doing so, they found that the stressed mice began to demonstrate reduced anxiety and depression.

By enhancing signaling across the CB1 receptors, vascular health was increased while brain inflammation was reduced, and the integrity of the BBB was protected—all factors contributing to mental well-being.

Diving Deeper

What is important to recognize is that the BBB acts as a critical protective threshold that separates the brain and the peripheral circulatory system.  In doing so, it regulates the entry of inflammatory molecules while maintaining homeostasis.  This is why chronic stress, which has been linked to BBB disruption, often leads to increased inflammation and mood disorders.

In this study, resilient mice maintained BBB integrity while stress-susceptible mice exhibited increased permeability, allowing inflammatory cytokines to infiltrate the brain.

So, when the researchers enhanced CB1 receptor expression in astrocytes, they were able to reduce BBB disruptions and the associated depressive-like behaviors.  On the flip side, these findings were further supported as mice engineered to lack CB1 receptors on astrocytes displayed heightened sensitivity to stress, reinforcing the protective role of these receptors.

Cannabinoid-Based Compounds in Mental Health

Looking beyond this study, recent research has found increasing evidence that cannabinoids and related compounds have shown promise in modulating stress and anxiety:

• Cannabigerol (CBG): CBG is a non-psychoactive cannabinoid found in cannabis.  Recent clinical trials suggest that CBG may have therapeutic effects on anxiety and stress while also improving memory. These findings indicate that CBG could complement CB1-targeted treatments in the development of stress resilience therapies.
• D-Limonene: A terpene commonly found in citrus fruits and cannabis, D-Limonene has been studied for its potential to reduce anxiety associated with THC consumption. Research suggests that it may counteract some of the anxiety-inducing effects of cannabis, making it a potential adjunct for individuals using cannabis-derived treatments for stress and anxiety.

Potential for Targeted Therapies

While the study highlights the protective role of CB1 receptors in astrocytes, it is important to remember that cannabis itself broadly activates CB1 receptors, including in neurons.  As a result, this can lead to side effects such as decreased alertness, appetite changes, and more.  The goal is to find derivatives of cannabis that can be used as future treatments by developing compounds that specifically target astrocytic CB1 receptors while minimizing unwanted effects on neuronal activity.  Interestingly, another recent study did just that.

Although the study focused on addressing pain rather than mental health disorders, it is the approach that is of note.  Researchers found that by modifying a cannabinoid compound so that it had a positive electrical charge, they were able to prevent it from crossing the BBB.  This allowed for the compound to work as intended on easing pain, while avoiding any of the associated symptoms resulting from crossing the BBB as previously discussed.

Simply put, the researchers were able to selectively activate CB1 receptors.  Gaining the ability to target CB1 receptors outside the central nervous system represents a significant advancement, providing a new avenue for cannabinoid-based therapies that mitigate stress-related disorders and chronic pain while avoiding traditional cannabis-related side effects.  Advances in synthetic cannabinoids and selective receptor modulators may provide targeted approaches to stress resilience without the drawbacks associated with broad CB1 activation.

Final Thoughts

Overall, this latest bit of research provides compelling evidence that astrocytic CB1 receptors play a crucial role in stress resilience by maintaining BBB integrity and reducing inflammation.  The findings could eventually open the door to new approaches for manipulating/leveraging CB1 receptors in astrocytes to enhance mental health resilience.  Until such treatments are available, individuals can potentially increase their CB1 receptor levels through physical activity and other lifestyle modifications.

Studies Referenced:

^{1. Dudek, K. A., Paton, S. E. J., Binder, L. B., Collignon, A., Dion-Albert, L., Cadoret, A., Lebel, M., Lavoie, O., Bouchard, J., Kaufmann, F. N., Clavet-Fournier, V., Manca, C., Guzmán, M., Campbell, M., Turecki, G., Mechawar, N., Flamand, N., Lavoie-Cardinal, F., Silvestri, C., … Ménard, C. (2025). Astrocytic cannabinoid receptor 1 promotes resilience by dampening stress-induced blood–brain barrier alterations. Nature Neuroscience. https://doi.org/10.1038/s41593-025-01891-9}